Repros Therapeutics

Repros Therapeutics — Investor Presentation (February 2008)

32 slides from Repros Therapeutics's investor presentation, Feb 12, 2008

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements and information regarding the future performance and actions of Repros Therapeutics Inc. (RPRX) that involve risks and uncertainties that could cause actual results and actions to differ materially. These risks include

  3. Slide 3: Repros Strategy

    Slide 3: Repros Strategy

    Repros Strategy Seek maximum return on shareholder investment through corporate transaction Focus on small molecule therapeutics for hormonal and reproductive system disorders that exhibit significant market potential and that are currently underserved Late stage development of highly differentiated

  4. Slide 4: Repros Market Opportunity

    Slide 4: Repros Market Opportunity

    Repros Market Opportunity Proellex Uterine fibroid anemia $140 million/year Uterine fibroid symptoms $1.75 billion/year Endometriosis symptoms $1.70 billion/year Androxal Fertility preservation $250 million/year Metabolic syndrome $>1 billion/year 2^ hypogonadism ex-US $100 million/year Total Potent

  5. Slide 5: Repros Pipeline

    Slide 5: Repros Pipeline

    Repros Pipeline Proellex® Anemia Initiating Pivotal Ph Uterine Fibroids Initiating Pivotal Endometriosis Androxal™ Fertility Maintenance & Improvement 4 Metabolic Syndrome* * treatment of men with idiopathic adult onset hypogonadatrophic hyponogandism associated with glycemic and lipid Gysreguiation

  6. Slide 6: Proellex

    Slide 6: Proellex

    Représ Proellex®

  7. Slide 7: Proellex Overview

    Slide 7: Proellex Overview

    Proellex Overview New class of selective progesterone receptor modulator (SPRM) Suitable for chronic and acute indications Potential significant advantages over existing GnRHa standard of care No loss of bone mineral density in clinical trials No chronic drug treatments available Excellent, long-ter

  8. Slide 8: Basis for New IND for Proellex in Pre-Surgical Treatment of Anemia

    Slide 8: Basis for New IND for Proellex in Pre-Surgical Treatment of Anemia

    Basis for New IND (submitted Q1'08) for Proellex for the Pre-Surgical Treatment of Anemia Associated with Uterine Fibroids BL Mo 1 Mo 2 Mo 3 Placebo 10.6 10.6 10.5 10.2 Median Hemoglobin g/DL p < 0.002 vs Pl 1 g increase = ~1 pint of blood Results from US Phase IIb Study Roughly 40% of women seeking

  9. Slide 9: Uterine Fibroids Large Underserved Market

    Slide 9: Uterine Fibroids Large Underserved Market

    Uterine Fibroids Large Underserved Market Most common tumor of the female reproductive tract Heavy bleeding / anemia Abdominal pressure / pain / urinary frequency Conservative Estimate, 15% of women of reproductive age with symptomatic uterine fibroids Potentially 26,000,000 women in US, Japan, Fran

  10. Slide 10: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids

    Slide 10: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids

    Key Symptom Driving Women to Seek Therapy for Uterine Fibroids Excessive Menstrual Bleeding Spotting Light Moderate Heavy 12.5 0.8 0.4 2.2 0.4 25 1.8 2.2 0.4 0.4 50 3.6 0.4 0.6 0.4 Lupron 8.6 2.4 1.6 2.4 Placebo 13.4 7.6 8.6 2.2 European Pilot Study (n=30) BL Mo 1 Mo 2 Mo 3 Placebo 113.5 91 83 69 P<

  11. Slide 11: Uterine Fibroid Symptom and Quality of Life Results

    Slide 11: Uterine Fibroid Symptom and Quality of Life Results

    BL MO 1 Mo 2 Mo 3 Placebo 56.3 37.5 37.5 37.5 Phase 2 Uterine Fibroid Trial UFSQOL UFSQOL Uterine Fibroid Symptom Survey High score > severity Month 3 significance values v.s. placebo; 25 mg p <0.0001 Spies et al, Obstetrics & Gynecology, vol. 99, No. 2, February 2002

  12. Slide 12: Comparison of Published Data for Uterine Artery Embolization and Proellex

    Slide 12: Comparison of Published Data for Uterine Artery Embolization and Proellex

    Comparison of Published Data for Uterine Artery Embolization and Proellex 25 mg at 3 Months of Treatment UAE data from Smith et al, 2004 Not adjusted for baseline p< 0.0001 compared to placebo

  13. Slide 13: Quality of Life: Uterine Artery Embolization vs Proellex 25 mg

    Slide 13: Quality of Life: Uterine Artery Embolization vs Proellex 25 mg

    Concern Activities Energy/Mood Control Self-Conscious Sexual Function Total HRQL Uterine Fibroid Patients 55.2 67.1 64.1 62.3 57.2 65 62.6 Normal Women 84 90.8 83.9 93 79 80.2 86.4 Placebo 61.6 71.2 72.8 74.7 62.4 74.6 69.9 Proellex 25mg 86.6 88.4 81.6 85.7 74.5 80 84 Uterine Artery Embolization 82.

  14. Slide 14: Endometriosis

    Slide 14: Endometriosis

    Endometriosis Epithelial & stromal endometrial cells outside the uterine cavity Pelvic and back pain Infertility Pain during sex Severe menstrual cramps 5% of reproductive-age women - more that are undiagnosed 71-87% of women with chronic pelvic pain 25-40% (2-4 million) infertility cases could be d

  15. Slide 15: Endometriosis Large Untapped Market

    Slide 15: Endometriosis Large Untapped Market

    Endometriosis Large Untapped Market 17 million potential patients $1.2B spent in major healthcare markets worldwide This despite poor treatment options and poor diagnosis "Gold Standard" care GnRHa limited to 6 months 71-87% of women with chronic pelvic pain 25-40% (2-4 million) infertility cases co

  16. Slide 16: Key Symptom Driving Women to Seek Therapy for Endometriosis

    Slide 16: Key Symptom Driving Women to Seek Therapy for Endometriosis

    Key Symptom Driving Women to Seek Therapy for Endometriosis Pelvic Abdominal Pain Fewer mean days of pain with 50mg Proellex (higher percentage of pain free days than with Lupron) p< 0.05 Lupron not statistically different than 25mg Proellex dose % Pain Free Days As Reported thru Month 6 Results of

  17. Slide 17: European Endometriosis Pilot Study

    Slide 17: European Endometriosis Pilot Study

    European Endometriosis Pilot Study Days of Any Pelvic/Abdominal Pain Lupron 25 mg 50 mg 101 74 86 3 105 24 16 0 109 7 19 13 115 166 57 1 203 13 55 1 206 8 33 0 218 51 40 6 213 8 33 9 22 19 6 8

  18. Slide 18: Proellex Safety Experience

    Slide 18: Proellex Safety Experience

    Proellex Safety Experience Well tolerated at all doses Potential for break through vaginal bleeding significantly reduced by incorporating "off-drug" intervals Open-label extension study confirming positive impact of "off-drug" interval

  19. Slide 19: Off Drug Interval Treatment Strategy

    Slide 19: Off Drug Interval Treatment Strategy

    "Off Drug Interval" Treatment Strategy 4 Month Dosing Cycle 4 Month Dosing Cycle 4 Month Dosing Cycle Off Drug Interval to allow for: Menses Refresh the endometrium Experience to date suggests menses returns in 25-35 days Return of symptoms Continue as needed Concept has been accepted by the FDA as

  20. Slide 20: Proellex Summary of FDA Meetings

    Slide 20: Proellex Summary of FDA Meetings

    Proellex Summary of FDA meetings FDA will entertain multiple label indications First NDA: Preoperative treatment of Anemia 2nd NDA: Chronic treatment of symptoms associated with fibroids 3rd NDA: Chronic treatment of symptoms of endometriosis Initial Phase III program - anemia and fibroids Two 65-pa

  21. Slide 21: Proellex Market Opportunity

    Slide 21: Proellex Market Opportunity

    Proellex Market Opportunity Proellex Uterine fibroid anemia $140 million/year Uterine fibroid symptoms $1.75 billion/year Endometriosis symptoms $1.70 billion/year Proellex Opportunity +$3.5 billion/year

  22. Slide 22: Androxal

    Slide 22: Androxal

    Représ Androxal

  23. Slide 23: Androxal

    Slide 23: Androxal

    Androxal Trans isomer of clomiphene citrate Cis isomer opposes action and has increased side effect risk Antiestrogen that normalizes pituitary responsiveness in 2^ hypogonadal men Highly statistically significant results in 6 month Phase III study showing restoration of pituitary responsiveness res

  24. Slide 24: Androxal Regulatory Strategy

    Slide 24: Androxal Regulatory Strategy

    Androxal Regulatory Strategy Primary focus on development of therapy to treat conditions associated with Metabolic Syndrome (estimated 15-20% of the male population) Insulin resistance Elevated glucose Elevated triglycerides Delay onset of Type II diabetes in the aging male Secondary focus on the pr

  25. Slide 25: Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome

    Slide 25: Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome

    Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome T<280 T>280 East 4.3 7.4 American Heart Association definition of Metabolic Syndrome Elevated waist circumference, ^ 40" Triglycerides, ^ 150 mg/dl Reduced HDL, < 40 mg/dl Elevated Blood Pressure, ^ 130/85 Elevated Fasting Glucose,

  26. Slide 26: Scientific Rationale for Androxal Effects and Clinical Need

    Slide 26: Scientific Rationale for Androxal Effects and Clinical Need

    Scientific Rationale for Androxal Effects and Clinical Need Recently published article suggests benefit of normal testosterone in the aging male In men age 50 -91 followed for 11+ years T < 240 ^g/dl 40% more likely to die Low T predicts increased risk of Cardiovascular disease Respiratory disease C

  27. Slide 27: Change in Serum Glucose

    Slide 27: Change in Serum Glucose

    Change in Serum Glucose Subset of Men BMI>26, Glucose >99 (+50% patients studied) 0 1 2 3 Androxal Pooled 0 -15 -16 -23 No significant change in Placebo or Androgel arms Significant mean change in Androxal arm p<0.01 0 1 2 3

  28. Slide 28: Impact of Androxal on Male Fertility

    Slide 28: Impact of Androxal on Male Fertility

    Impact of Androxal on Male Fertility Baseline 6 Months Androgel 5.42 1.1 12.5 mg Androxal 7.02 9.1 25 mg Androxal 6.4 11.8 Comparison of Means p=0.011 Comparison of Median p=0.0045 Estimated 1/3 of current T market ($750 million) are men of reproductive age 32% of men in Repros study under age of 50

  29. Slide 29: Androxal Market Opportunity

    Slide 29: Androxal Market Opportunity

    Androxal Market Opportunity Androxal Fertility preservation in 2^ hypogonadism $250 million/yr Metabolic Syndrome +$1 billion/yr Ex-US treatment of 2^ hypogonadism $100 million/yr Androxal Opportunity >$1.35 billion

  30. Slide 30: Repros Fundamentals

    Slide 30: Repros Fundamentals

    Repros Fundamentals Shares Outstanding 12,774,904 (all common, no warrants) 2005 Cash Burn $7,391,000 2006 Cash Burn $14,195,000 (no debt) Burn 2007 ~$14,400,000 Unaudited Cash on 2/4/08 : approximately $23.4million

  31. Slide 31: Recent and Upcoming Milestones & Goals

    Slide 31: Recent and Upcoming Milestones & Goals

    Recent and Upcoming Milestones & Goals 2Q07 Reported top-line Proellex Phase 2b fibroid data 3Q07 Commenced US Proellex Phase 2 endometriosis trial 3Q07 Reported non-pivotal Phase 3 Androxal data 1Q08 Submitted Anemia IND 1Q08 Commence Phase 3 registration trials for Anemia 1Q08 Commence Phase 3 reg

  32. Slide 32: Thank you

    Slide 32: Thank you

    Représ Thank you

Source: SEC EDGAR · 8-K filed Feb 12, 2008

More decks from Repros Therapeutics